These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 15778575)

  • 1. Pharmacokinetics and clinical evaluation of 125I-radiolabeled humanized CC49 monoclonal antibody (HuCC49deltaC(H)2) in recurrent and metastatic colorectal cancer patients.
    Xiao J; Horst S; Hinkle G; Cao X; Kocak E; Fang J; Young D; Khazaeli M; Agnese D; Sun D; Martin E
    Cancer Biother Radiopharm; 2005 Feb; 20(1):16-26. PubMed ID: 15778575
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intraoperative detection of occult colon cancer micrometastases using 125 I-radiolabled monoclonal antibody CC49.
    Cote RJ; Houchens DP; Hitchcock CL; Saad AD; Nines RG; Greenson JK; Schneebaum S; Arnold MW; Martin EW
    Cancer; 1996 Feb; 77(4):613-20. PubMed ID: 8616751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pilot study using a humanized CC49 monoclonal antibody (HuCC49DeltaCH2) to localize recurrent colorectal carcinoma.
    Agnese DM; Abdessalam SF; Burak WE; Arnold MW; Soble D; Hinkle GH; Young D; Khazaeli MB; Martin EW
    Ann Surg Oncol; 2004 Feb; 11(2):197-202. PubMed ID: 14761924
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and tumor localization of (111)in-labeled HuCC49DeltaC(H)2 in BALB/c mice and athymic murine colon carcinoma xenograft.
    Chinn PC; Morena RA; Santoro DA; Kazules T; Kashmiri SV; Schlom J; Hanna N; Braslawsky G
    Cancer Biother Radiopharm; 2006 Apr; 21(2):106-16. PubMed ID: 16706631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors influencing the pharmacokinetics, dosimetry, and diagnostic accuracy of radioimmunodetection and radioimmunotherapy of carcinoembryonic antigen-expressing tumors.
    Behr TM; Sharkey RM; Juweid MI; Dunn RM; Ying Z; Zhang CH; Siegel JA; Gold DV; Goldenberg DM
    Cancer Res; 1996 Apr; 56(8):1805-16. PubMed ID: 8620497
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of iodine-125 CC49 monoclonal antibody in patients with colon cancer.
    Cook CH; Hinkle GH; Thurston MO; Martin EW
    Cancer Biother Radiopharm; 1996 Dec; 11(6):415-22. PubMed ID: 10851502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intraoperative detection of colorectal cancer with radioimmunoguided surgery and CC49, a second-generation monoclonal antibody.
    Arnold MW; Schneebaum S; Berens A; Petty L; Mojzisik C; Hinkle G; Martin EW
    Ann Surg; 1992 Dec; 216(6):627-32. PubMed ID: 1466615
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel monoclonal antibody design for radioimmunotherapy.
    Forero A; Meredith RF; Khazaeli MB; Carpenter DM; Shen S; Thornton J; Schlom J; LoBuglio AF
    Cancer Biother Radiopharm; 2003 Oct; 18(5):751-9. PubMed ID: 14629823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pilot study evaluating the intraoperative localization of radiolabeled monoclonal antibody CC83 in patients with metastatic colorectal carcinoma.
    Burak WE; Schneebaum S; Kim JA; Arnold MW; Hinkle G; Berens A; Mojzisik C; Martin EW
    Surgery; 1995 Jul; 118(1):103-8. PubMed ID: 7604370
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of recombinant alpha-interferon on pharmacokinetics, biodistribution, toxicity, and efficacy of 131I-labeled monoclonal antibody CC49 in breast cancer: a phase II trial.
    Macey DJ; Grant EJ; Kasi L; Rosenblum MG; Zhang HZ; Katz RL; Rieger PT; LeBherz D; South M; Greiner JW; Schlom J; Podoloff DA; Murray JL
    Clin Cancer Res; 1997 Sep; 3(9):1547-55. PubMed ID: 9815842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Actinium-225 conjugates of MAb CC49 and humanized delta CH2CC49.
    Kennel SJ; Brechbiel MW; Milenic DE; Schlom J; Mirzadeh S
    Cancer Biother Radiopharm; 2002 Apr; 17(2):219-31. PubMed ID: 12030116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pilot radioimmunotherapy trial with 131I-labeled murine monoclonal antibody CC49 and deoxyspergualin in metastatic colon carcinoma.
    Divgi CR; Scott AM; Gulec S; Broussard EK; Levy N; Young C; Capitelli P; Daghighian F; Williams JM; Finn RD
    Clin Cancer Res; 1995 Dec; 1(12):1503-10. PubMed ID: 9815950
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A CDR-grafted (humanized) domain-deleted antitumor antibody.
    Slavin-Chiorini DC; Kashmiri SV; Lee HS; Milenic DE; Poole DJ; Bernon E; Schlom J; Hand PH
    Cancer Biother Radiopharm; 1997 Oct; 12(5):305-16. PubMed ID: 10851481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radioimmunoguided surgery in colorectal cancer using a genetically engineered anti-CEA single-chain Fv antibody.
    Mayer A; Tsiompanou E; O'Malley D; Boxer GM; Bhatia J; Flynn AA; Chester KA; Davidson BR; Lewis AA; Winslet MC; Dhillon AP; Hilson AJ; Begent RH
    Clin Cancer Res; 2000 May; 6(5):1711-9. PubMed ID: 10815889
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radioimmunoguided surgery for colorectal cancer.
    Manayan RC; Hart MJ; Friend WG
    Am J Surg; 1997 May; 173(5):386-9. PubMed ID: 9168072
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose therapy with iodine-131-labeled monoclonal antibody CC49 in patients with gastrointestinal cancers: a phase I trial.
    Tempero M; Leichner P; Dalrymple G; Harrison K; Augustine S; Schlam J; Anderson J; Wisecarver J; Colcher D
    J Clin Oncol; 1997 Apr; 15(4):1518-28. PubMed ID: 9193348
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radioimmunoguided-intraoperative radiation therapy in colorectal carcinoma: a new technique to precisely define the clinical target volume.
    Nag S; Martinez-Monge R; Nieroda C; Martin E
    Int J Radiat Oncol Biol Phys; 1999 Apr; 44(1):133-7. PubMed ID: 10219806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intra-abdominal patterns of disease dissemination in colorectal cancer identified using radioimmunoguided surgery.
    Arnold MW; Hitchcock CL; Young DC; Burak WE; Bertsch DJ; Martin EW
    Dis Colon Rectum; 1996 May; 39(5):509-13. PubMed ID: 8620799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Phase I study of combined modality (90)Yttrium-CC49 intraperitoneal radioimmunotherapy for ovarian cancer.
    Alvarez RD; Huh WK; Khazaeli MB; Meredith RF; Partridge EE; Kilgore LC; Grizzle WE; Shen S; Austin JM; Barnes MN; Carey D; Schlom J; LoBuglio AF
    Clin Cancer Res; 2002 Sep; 8(9):2806-11. PubMed ID: 12231520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I therapy study with (186)Re-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with head and neck squamous cell carcinoma.
    Börjesson PK; Postema EJ; Roos JC; Colnot DR; Marres HA; van Schie MH; Stehle G; de Bree R; Snow GB; Oyen WJ; van Dongen GA
    Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3961S-72S. PubMed ID: 14506195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.